Follistatin and Systolic Function at Follow-Up in STEMI Patients: A Cardiac Magnetic Resonance Study

Area of Science:

• Cardiology
• Biomarker Discovery
• Myocardial Infarction Research

Background:

• Limited early biomarkers exist to predict left ventricular (LV) systolic function recovery after ST-segment elevation myocardial infarction (STEMI).
• Assessing serum follistatin's association with long-term LV systolic function post-reperfusion is crucial.

Purpose of the Study:

• To investigate if early serum follistatin levels correlate with long-term LV systolic function after STEMI.
• To explore follistatin as a potential predictive biomarker for cardiac recovery.

Main Methods:

• Prospective study of 31 STEMI patients undergoing coronary revascularization.
• Serial cardiac magnetic resonance (CMR) imaging at 1 week and 6 months.
• Serum follistatin measured within 24 hours post-revascularization; statistical analysis of associations.

Main Results:

• Higher serum follistatin levels were associated with improved LV ejection fraction (LVEF) at 6 months.
• Follistatin independently predicted better LVEF and greater LVEF improvement post-STEMI.
• No significant differences in LV function at 1 week between follistatin groups.

Conclusions:

• Early serum follistatin is a potential independent biomarker for predicting favorable long-term LV systolic function after STEMI.
• Follistatin may indicate subsequent systolic recovery, requiring further validation in larger studies.